

Effects of HERV-R env Knockdown in Combination with Ionizing Radiation on Apoptosis-Related Gene Expression in A549 Lung Cancer Cells

Ja-Rang Lee¹, Yi-Deun Jung², Young-Hyun Kim^{1,3}, Sang-Je Park¹, Jae-Won Huh^{1,3*} and Heui-Soo Kim^{4**}

¹National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju 363-883, Republic of Korea

²Stem Cell Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea

³University of Science and Technology, National Primate Research Center, KRIBB, Cheongju 363-883, Republic of Korea

⁴Department of Biological Sciences, College of Natural Sciences, Pusan National University, Busan, Republic of Korea

Abstract

Radiotherapy has played a key role in the management of non-small-cell lung cancer (NSCLC). However, the use of radiotherapy in treating NSCLC is limited because of the intrinsic radiation resistance of tumor cells and injury to adjacent normal tissues. Many oncogenes are reported to be involved in radioresistance. Thus, novel molecular-targeting approaches to enhance the radiosensitivity of NSCLC cells are required to improve the therapeutic efficiency of radiotherapy. In this study, we report that expression of the human endogenous retrovirus-R (HERV-R) *env* gene is greatly elevated in γ -irradiation resistant A549 cells compared with radiation sensitive H460 cells. In addition, the HERV-R *env* gene was significantly increased in A549 cells after treatment with γ -irradiation. HERV-R *env* knockdown by siRNA in irradiated A549 cells led to overexpression of *TP53* mRNA, followed by significant elevation in the levels of *CDKN1A* mRNA. Moreover, the expression of the apoptosis-related *FAS-1* gene was increased, whereas the expression levels of the anti-apoptotic gene *BCL2* were significantly decreased in the A549 cells in which the HERV-R *env* was suppressed by γ -irradiation. These results suggest that knockdown of HERV-R *env* with γ -irradiation causes cell cycle disturbances, which in turn induces apoptosis. In conclusion, the combination of HERV-R *env* knockdown and γ -irradiation has the potential to improve the therapeutic efficiency of radiotherapy for NSCLC.

Keywords: Non-small-cell lung cancer (NSCLC); Radioresistance; HERV-R *env*; γ -irradiation

Introduction

Ionizing radiation has been widely used for the treatments of many tumors, either alone or in combination with chemotherapy. However, radiation therapy has limitations because of the intrinsic radioresistance of tumors and the occurrence of injury to adjacent normal tissues, such as the heart, liver, and lung, which are important clinical problems [1]. A number of oncogenes and tumor suppressor genes have been suggested to play important roles in radiosensitivity. For example, expression of oncogenes including *Ras*, *Myc*, *Raf*, and mutated *TP53* correlates with radioresistance in many tumor cells [2-6], whereas tumor suppressor genes including wild-type *TP53* and *p16* are closely linked to radiosensitivity [7,8]. Thus, cancer-related genes may be involved in radioresistance.

Human endogenous retroviruses (HERVs) occupy about 8% of the human genome [9] and have been derived from exogenous retroviruses by ancient germ cell infection [10]. Most HERV sequences have defective structures, such as truncations, deletions, and insertions. However, some HERV families, or family members, retain full-length sequences containing a functional open reading frame (ORFs) in the *env* region [11]. These *env* genes are expressed in particular physiological contexts and in various human diseases [12,13]. Moreover, proviruses driving the expression of their own retroviral proteins have physiological functions, for example in promoting cell proliferation, cell-cell fusion, anti-apoptotic functions, and immunosuppression [14-17]. A HERV *env* genes also appear strictly expressed in various cancers, including ovarian, prostate, and breast cancers, and melanoma [18-22].

HERV-R is located on human chromosome 7 and has an intact ORF in the *env* region, encoding a protein with surface unit (SU) and transmembrane (TM) domains [23,24]. The HERV-R envelope protein contains a putative immunosuppressive domain, and the TM domain may be involved in cell-cell fusion. Therefore, the HERV-R envelope protein could potentially contribute to the formation of

syncytiotrophoblast in the placental chorionic villi during gestation [25-27]. Nevertheless, the TM retroviral protein enhances tumorigenicity, and is involved in autoimmune diseases, including type I diabetes. Three *env*-containing mRNAs are transcribed from HERV-R: a 3.5-kb transcript comprising only proviral sequences and 7.3-kb and 9-kb transcripts that extend downstream of the provirus [23]. HERV-R mRNAs are expressed in normal tissues in the brain, prostate, testis, kidney, placenta, thymus, and uterus [28]. HERV-R *env* is regulated by various endogenous and exogenous stimulants, for example cytokines, steroids, drugs, or ionizing radiations [29-32]. In particular, γ -irradiation induces upregulation of HERV-R *env* expression in normal human cell lines [32]. The regulation of expression via γ -irradiation is based on epigenetic control mechanisms, including histone modification. Expression of HERV-R *env* is also elevated in liver and lung cancers compared to that in adjacent non-tumor tissues [33]. Thus, HERV-R *env* is a potential biomarker for liver and lung cancers; however, the role of HERV-R *env* in the cancers is yet to be elucidated.

In this study, the differential expression of HERV-R *env* in fractionated, γ -irradiation-treated lung cancer cell lines was observed,

***Corresponding authors:** Heui-Soo Kim, Department of Biological Sciences, College of Natural Sciences, Pusan National University, Busan 609-735, Korea, Tel: +82-51-510-2259; Fax: +82-51-581-2962; E-mail: khs307@pusan.ac.kr

Jae-Won Huh, National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju, Korea, Tel: +82-43-240-6327; Fax: +82-43-240-6309; E-mail: huhjw@kribb.re.kr

Received January 07, 2016; Accepted February 23, 2016; Published March 01, 2016

Citation: Lee JR, Jung YD, Kim YH, Park SJ, Huh JW, et al. (2016) Effects of HERV-R env Knockdown in Combination with Ionizing Radiation on Apoptosis-Related Gene Expression in A549 Lung Cancer Cells. Biochem Physiol 5: 200. doi: 10.4172/2168-9652.1000200

Copyright: © 2016 Lee JR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

and the role of HERV-R *env* in cell radioresistance was investigated using knockdown experiments. HERV-R *env* knockdown in fractionated, γ -irradiated cells was observed to induce upregulation of apoptosis-related genes.

Materials and Methods

Cell culture and ionizing radiation

A549 and H460 cells were grown in RPMI1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin and maintained in a humidified, 5%-CO₂ atmosphere at 37°C. For irradiation, cells were seeded in 60-mm cell culture dishes, allowed to grow to 60–80% confluence, and then irradiated with 2 Gy per day. Total gamma-irradiation (Cs-137) doses were 2 Gy, 4 Gy, and 6 Gy at a dose of 0.81 Gy/min. Experiments were performed in triplicate. All irradiations were performed using a Gamma Cell 1000 Elan (Nordion International, Inc., Ontario, Canada). Dishes containing control cells were taken to the irradiation chamber, but were not exposed to radiation.

In vitro siRNA treatment

siRNA targeting HERV-R *env* (5'-AGG CAU AAC UAU AGG AGA U-3') and negative siRNA were purchased from RNAi Co. (Bioneer, Korea). Cells were transfected with 100 nM siRNA by using the Lipofectamine 2000 transfection reagent (Invitrogen). The cells were incubated for 24 h after transfection, and then HERV-R *env* expression was determined by means of real-time reverse transcription polymerase chain reaction (RT-PCR).

RNA isolation and cDNA synthesis

A549 and H460 cells were trypsinized, washed with phosphate-buffered saline (PBS), followed by total RNA extraction using a High Pure RNA isolation kit (Roche). For cDNA synthesis, 1 μ g of pure mRNA was reverse-transcribed in a 20 μ L reaction volume containing 10 pmol oligo-dT, M-MLV reverse transcriptase, and the corresponding buffer. The reaction was carried out at 42°C for 90 min and terminated by heating for 2 min at 95°C.

Real-time RT-PCR and statistical analyses

HERV-R *env*, radioresistance, and apoptosis-related genes were analysed by means of real-time RT-PCR amplification. We also performed real-time RT-PCR amplification on pure mRNA samples without a reverse transcription reaction to confirm that the prepared mRNA samples did not contain genomic DNA. All the primers used in this study and their sequences are listed in Table 1. For normalization, glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) was amplified. The amplification efficiencies and correlation coefficients (R²) of the *env* gene were determined from the slopes of the standard curves that were obtained using a serial dilution series. Each primer pair exhibited a single, sharp peak, indicating that the primers amplified only one specific PCR product. Primer dimers were not observed. The sample was added to a 19 μ L reaction mixture containing 7 μ L H₂O, 10 μ L QuantiTect SYBR Green PCR Master Mix (Qiagen, Valencia, CA), and 1 μ L each of the forward and reverse primers. Real-time RT-PCR was performed in a Rotor Gene 3000 (Corbett Research, Australia) for 50 cycles of 94°C for 10 s, 58°C for 15 s, and 72°C for 15 s. Melting curve analyses were carried out for 30 s at 55–99°C. All samples were amplified in triplicate. The statistical significance of the differences between two groups was determined using two-tailed Student's *t*-test. $P < 0.05$ was considered to indicate a statistically significant difference.

Primer Name	Sequence	GenBank accession no.
HERV-R <i>env</i>	S : 5'-CAT GGG AAG CAA GGG AAC T -3'	AC073210
	AS : 5'-CTT TCC CCA GCG AGC AAT AC -3'	
GP96	S : 5'-TGA GGAAGC GAG TAA CCA-3'	NM_021141
	AS : 5'-GTC CAC ATC ACC ACC TTC-3'	
GDF15	S : 5'-AGA TCA AGA CGA GCC TGC ACC-3'	NM_004864
	AS : 5'-CAT TCC ACA GGG CAG GAC AA-3'	
TP53	S : 5'-CTG GCC CCT GTC ATC TTC TG-3'	NM_001126118
	AS : 5'-CCG TCA TGT GCT GTG ACT GC-3'	
CDKN1A	S : 5'-GGC ACC TCA CCT GCT CTG-3'	NM_001220777
	AS : 5'-TGG TAG AAA TCT GTC ATG CTG G-3'	
FAS-1	S : 5'-CAA GGG ATT GGA ATT GAG CA-3'	NM_000043
	AS : 5'-GAC AAA GCC ACC CCAAGT TA-3'	
BCL2	S : 5'-AGG AAG TGA ACA TTT CGG TGA C-3'	NM_000633
	AS : 5'-GCT CAG TTC CAG GAC CAG GC-3'	
GAPDH	S : 5'-GAA GAT GGT GAT GGG ATT TC-3'	NM_002046
	AS : 5'-GAA GGT GAA GGT CGG AGT-3'	

Table 1: List of oligonucleotides used for quantitative real-time RT-PCR.

Results

Differential expression of radioresistance-related genes in 2 NSCLC cell lines

A549 lung adenocarcinoma cancer cells tend to be a more radioresistant phenotype than H460 lung cancer cells. Previous work has shown that A549 are more radioresistant than H460 cells [34,35]. We amplified the genes reported to contribute to radioresistance by using real-time RT-PCR [36,37]. GP96 and GDF-15 gene expressions were significantly increased in A549 cells compared to those in H460 cells (Figure 1). These data add weight to previous work that showed that A549 cells are more radioresistant than H460 cells.

Differential expression of HERV-R *env* in γ -irradiated lung cancer cells

To investigate differential expression of HERV-R *env* in γ -irradiated A549 and H460 cells, real-time RT-PCR analyses were performed using cells subjected to γ -irradiation at doses of 0 Gy, 2 Gy, 4 Gy, and




Figure 1: Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) analyses of radioresistance-related genes in A549 and H460 cells. Data represent the mean \pm SD (n = 3). Error bars indicate the standard deviation. Experiments were performed in triplicate to ascertain the reproducibility of the results (*** $P < 0.005$, * $P < 0.05$).

6 Gy (Figure 2). The mRNA levels of HERV-R *env* were significantly increased at 4 Gy and 6 Gy of γ -irradiation in A549 cells, but H460 cells did not show any trends of differential expression. We further observed that HERV-R *env* expression was upregulated by 4.8-fold and 5.4-fold in A549 cells after exposure to 4 Gy and 6 Gy of γ -radiation, respectively, compared to non-irradiated A549 cells. Furthermore, HERV-R *env* expression level was higher in A549 than in H460 cells after exposure to 4 Gy and 6 Gy of γ -radiation. These results suggest that HERV-R *env* expression in radioresistant cells is significantly increased by γ -irradiation.

Effect of siRNA transfection on HERV-R *env* expression

The knockdown efficiency of HERV-R *env* expression by HERV-R




Figure 2: Comparison of HERV-R *env* gene expression in A549 and H460 cells after γ -irradiation. Relative HERV-R *env* gene expression in A549 and H460 cells was compared. The ratio was determined from the mRNA level at 24 h after fractionated γ -irradiation at 2 Gy per day. Data represent the mean \pm SD (n = 3). Error bars indicate the standard deviation. Experiments were performed in triplicate to ascertain the reproducibility of the results (***P < 0.005, **P < 0.01, *P < 0.05).

siRNAs was evaluated in A549 cells. Using real-time RT-PCR, HERV-R *env* expression was found to be significantly reduced to $46.0 \pm 5.33\%$, $47.6 \pm 3.14\%$, and $21.8 \pm 6.32\%$ in mock transfected control cells in A549 cells transfected with 50 pmol, 80 pmol, and 100 pmol of siRNA, respectively (Figure 3A). The 100 pmol siRNA transfection generated the highest knockdown efficiency compared to the other concentrations. In addition, HERV-R *env* expression remained significantly decreased after HERV-R *env* siRNA treatment in γ -irradiated A549 cells (Figure 3B). HERV-R *env* expression was significantly reduced to $23.3 \pm 3.64\%$, $38.4 \pm 1.88\%$, and $29.6 \pm 2.18\%$, respectively, in HERV-R *env* siRNA-transfected A549 cells treated with 2 Gy, 4 Gy, and 6 Gy of fractionated γ -radiation.

HERV-R *env* knockdown induces upregulation of apoptosis related genes and downregulation of anti-apoptotic gene in radioresistant cells after γ -irradiation

To determine whether inhibition of HERV-R *env* sensitizes A549 cells to radiation, expression levels of apoptosis-related mRNAs were determined using real-time RT-PCR analysis. Levels of the *TP53* mRNA were significantly increased at 4 and 6 Gy of γ -irradiation in HERV-R *env* siRNA transfected A549 cells (Figure 4A). The *CDKN1A* mRNA was also upregulated by 10.7-, 24.0-, and 14.1-fold in HERV-R *env* siRNA transfected A549 cells after exposure to 2, 4, and 6 Gy of γ -irradiation, compared to non-irradiated A549 cells (Figure 4B). In addition, levels of *FAS-1* were increased at 2, 4, and 6 Gy of γ -irradiation, compared to non-irradiated A549 cells (Figure 4C). By contrast, expression of the *BCL2* gene was significantly decreased at 2, 4, and 6 Gy of γ -irradiation in HERV-R *env* siRNA transfected A549 cells (Figure 4D). These results suggest that knockdown of HERV-R *env* led to increased transcription of pro-apoptotic molecules, and decreased levels of anti-apoptotic markers in γ -irradiated A549 cells.




Figure 3: Suppressing the expression of HERV-R *env* by siRNA in A549. (A) Relative HERV-R *env* gene expression was significantly reduced in HERV-R *env* siRNA transfected A549 cells 24 h after transfection, as determined by quantitative real-time RT-PCR. (B) HERV-R *env* expression remained low in the negative control and HERV-R *env* siRNA-transfected A549 cells after exposure to fractionated γ -irradiation. Ratios were determined from the mRNA levels 24 h after exposure to fractionated γ -irradiation at 2 Gy per day. Data represent the mean \pm SD (n = 3). Error bars indicate the standard deviation. Experiments were performed in triplicate to ascertain the reproducibility of the results (***P < 0.005, **P < 0.01, *P < 0.05).




Figure 4: Fractionated γ -irradiation-induced apoptotic molecules activation in HERV-R *env* siRNA transfected A549 cells. (A) *TP53*, (B) *CDKN1A*, (C) *FAS-1*, and (D) *BCL2* gene expression levels were determined by real-time RT-PCR. Cells were γ -irradiated at fractionated doses of 2 Gy, 4 Gy, and 6 Gy 24 h after the transfection of negative control (white), or HERV-R *env*, siRNA (black). Data represent the mean \pm SD (n = 3). Error bars indicate the standard deviation. Experiments were performed in triplicate to ascertain the reproducibility of the results (** $P < 0.005$, ** $P < 0.01$, * $P < 0.05$).


Discussion

Many lung cancers, in particular non-small cell lung cancer (NSCLC), are highly aggressive tumors with very poor prognoses. One major treatment for lung cancer is radiotherapy; however, NSCLCs with intrinsic radio- and drug-resistance have been reported [38]. In addition, the response of NSCLCs with the same histology to radiations can vary substantially [34]. Therefore, it is important to improve the efficiency of radiotherapy, which could be achieved by adopting novel molecular-targeting approaches to increase the radiosensitivity of NSCLC cells [39,40]. In particular, A549 lung adenocarcinoma cancer cells have been reported to tend towards a more radioresistant phenotype compared with H460 lung cancer cells [34,35]. In this study, we investigated whether the HERV-R *env* gene is involved in radioresistance by comparing 2 NSCLC cell lines, A549 and H460. Our results confirmed the differences in the basal expression levels of radioresistance-related genes in response to radiation between A549 and H460 cells.

The radioresistance of cancer cells has been postulated to be under the control of various oncogenes [2-6]. Previous studies have provided evidence that the activity of retroelements, including HERV families, plays a distinct role in tumorigenesis and tumor progression via the activation of oncogenes or the expression of functional proteins, including immunosuppressive proteins [12,41]. In particular, the TM cytoplasmic YXXM motif in the jaagsiekte sheep retrovirus envelope protein has been shown to be tumorigenic both *in vitro* and *in vivo* [42]. In addition, the fusogenic HERV

envelope protein exerts anti-apoptotic function, and downregulates active caspase-3 expression [15]. HERV-R has been described as an active provirus containing a long ORF that includes the TM and SU domains in the *env* region that encodes viral envelope proteins. These *env* transcripts are often activated by environmental stress such as ionizing radiations, as well as by cytokines, steroids, and drugs [29-32]. Moreover, HERV-R *env* is overexpressed in lung and liver cancers compared with their adjacent non-tumor tissues [33]. However, whether the upregulation of HERV-R *env* by γ -irradiation plays a specific role in cancer is not yet known. Thus, we first investigated whether HERV-R *env* expression changed in response to γ -irradiation in A549 cells. In these cells, the expression of HERV-R *env* was significantly increased in a dose-dependent manner 24 h after fractionated γ -irradiation with 4 Gy and 6 Gy (Figure 2). However, no unusual expression of HERV-R *env* was observed in H460 cells. A notable increase in HERV-R *env* expression is triggered by exposure to ionizing radiation in radioresistant cells. This finding is of special interest, the results of the present study suggested for the first time that HERV-R *env* is potentially involved in the regulation of radioresistance in lung cancer cells.

Human *TP53* encodes the p53 nuclear protein, which is a transcription factor with tumor suppressor functions [43]. As a key regulator of cell growth and programmed cell death, DNA-damaging agents, including UV, ionizing radiations, and chemical agents, stimulate the expression levels of *TP53*. Activated p53 can induce cell cycle arrest at the G1/S DNA damage recognition regulation point [44,45]. *CDKN1A* encodes the p21 nuclear protein, also known as



cyclin-dependent kinase inhibitor 1, or CDK-interacting protein 1. *CDKN1A* expression is controlled by the p53 protein, and p21 regulates the p53-dependent cell cycle G1 phase arrest in response to DNA damage stimulants. In addition, p21 can prevent cell division after exposure to DNA-damaging agents, resulting in cell growth arrest [46]. *TP53* and *CDKN1A* genes are, therefore, representative apoptosis-related genes. Furthermore, the *FAS* gene encodes a member of the TNF-receptor superfamily and contains a death domain. This gene has been reported to play a key role in programmed cell death [47]. In this study, to demonstrate the radiosensitizing effects caused by HERV-R *env* knockdown, the abovementioned genes were used as apoptosis markers. Quantitative RT-PCR showed high levels of *TP53*, *CDKN1A*, and *FAS-1* mRNA expression in HERV-R *env* siRNA-transfected A549 cells that were subjected to γ -irradiation, compared to non-irradiated cells (Figure 4). These results demonstrate that HERV-R *env* knockdown cells subjected to γ -irradiation upregulate *TP53* expression in a dose-dependent manner, followed by induction of *CDKN1A* expression. Our observations suggest that the cell cycle arrest induced by HERV-R *env* knockdown in γ -irradiated cells might be mediated via functionally activated p53. Furthermore, we observed that genes positively regulating apoptosis, such as *TP53*, *CDKN1A*, and *FAS-1* were upregulated, but anti-apoptotic genes, including *BCL2*, were downregulated in HERV-R *env* siRNA-transfected A549 cells subjected to γ -irradiation; this was not the case in non-irradiated cells. These data suggest that HERV-R *env* knockdown may induces radiosensitizing effects via apoptosis and cell cycle arrest; however, further study will be necessary to confirm the phenotype and establish definitively the signalling pathway by which HERV-R *env* knockdown induces radiosensitization and programmed cell death.

In conclusion, this is the first study to demonstrate that HERV-R *env* may be involved in the radioresistance phenotype of NSCLC A549 cells. This study showed that HERV-R *env* mRNA levels increase after irradiation in A549 cells but not in H460 cells and that knockdown of HERV-R *env* mRNA increased *TP53*, *CDKN1A* and *FAS-1* mRNA while decreasing *BCL2* mRNA. These results suggests the radiosensitizing effects of HERV-R *env*, which is the target of the ionizing radiations, and could be of great use in understanding the role of active HERV elements in radioresistance (Figure 5). Taken together, these results indicating a possible role of HERV-R *env* in mediating radiation resistance and as such may be a useful target for novel anticancer strategies.

Acknowledgment

This research was supported by a grant from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (KGM4241642).

References

- Purdy JA (2008) Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. *Health Phys* 95: 666-676.
- Choi EJ, Ryu YK, Kim SY, Wu HG, Kim JS, et al. (2010) Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. *Mol Cancer Res* 8: 1027-1036.
- Su WH, Chuang PC, Huang EY, Yang KD (2012) Radiation-induced increase in cell migration and metastatic potential of cervical cancer cells operates via the K-Ras pathway. *Am J Pathol* 180: 862-871.
- Huang EY, Chen YF, Chen YM, Lin IH, Wang CC, et al. (2012) A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. *Cell Death Dis* 3: e251.
- Cui F, Fan R, Chen Q, He Y, Song M, et al. (2015) The involvement of c-Myc in the DNA double-strand break repair via regulating radiation-induced phosphorylation of ATM and DNA-PKcs activity. *Mol Cell Biochem* 406: 43-51.
- Ruan L, Wang GL, Yi H, Chen Y, Tang CE, et al. (2010) Raf kinase inhibitor protein correlates with sensitivity of nasopharyngeal carcinoma to radiotherapy. *J Cell Biochem* 110: 975-981.
- Cao L, Kawai H, Sasatani M, Iizuka D, Masuda Y, et al. (2014) A novel ATM/TP53/p21-mediated checkpoint only activated by chronic β -irradiation. *PLoS One* 9: e104279.
- Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, et al. (2015) Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. *Radiother Oncol* 115: 120-127.
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. *Nature* 409: 860-921.
- Löwer R, Löwer J, Kurth R (1996) The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. *Proc Natl Acad Sci U S A* 93: 5177-5184.
- Villesen P, Aagaard L, Wiuf C, Pedersen FS (2004) Identification of endogenous retroviral reading frames in the human genome. *Retrovirology* 1: 32.
- Nadeau MJ, Manghera M, Douville RN (2015) Inside the Envelope: Endogenous Retrovirus-K Env as a Biomarker and Therapeutic Target. *Front Microbiol* 6: 1244.
- Duperray A, Barbe D, Raguenez G, Weksler BB, Romero IA, et al. (2015) Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. *Int Immunol* 27: 545-553.
- Frendo JL, Olivier D, Cheynet V, Blond JL, Bouton O, et al. (2003) Direct

- involvement of HERV-W Env glycoprotein in human trophoblast cell fusion and differentiation. *Mol Cell Biol* 23: 3566-3574.
15. Knerr I, Schnare M, Hermann K, Kausler S, Lehner M, et al. (2007) Fusogenic endogenous-retroviral syncytin-1 exerts anti-apoptotic functions in staurosporine-challenged CHO cells. *Apoptosis* 12: 37-43.
 16. Mangeney M, Renard M, Schlecht-Louf G, Bouallaga I, Heidmann O, et al. (2007) Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins. *Proc Natl Acad Sci U S A* 104: 20534-20539.
 17. Strick R, Ackermann S, Langbein M, Swiatek J, Schubert SW, et al. (2007) Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-beta. *J Mol Med (Berl)* 85: 23-38.
 18. Li Z, Sheng T, Wan X, Liu T, Wu H, et al. (2010) Expression of HERV-K correlates with status of MEK-ERK and p16INK4A-CDK4 pathways in melanoma cells. *Cancer Invest* 28: 1031-1037.
 19. Wang-Johanning F, Frost AR, Jian B, Azerou R, Lu DW, et al. (2003) Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma. *Cancer* 98: 187-197.
 20. Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, et al. (2007) Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. *Int J Cancer* 120: 81-90.
 21. Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, et al. (2012) Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. *J Natl Cancer Inst* 104: 189-210.
 22. Zhao J, Rycaj K, Geng S, Li M, Plummer JB, et al. (2011) Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer. *Genes Cancer* 2: 914-922.
 23. O'Connell CD, Cohen M (1984) The long terminal repeat sequences of a novel human endogenous retrovirus. *Science* 226: 1204-1206.
 24. O'Connell C, O'Brien S, Nash WG, Cohen M (1984) ERV, a full-length human endogenous provirus: chromosomal localization and evolutionary relationships. *Virology* 138: 225-235.
 25. Larsson E, Andersson AC, Nilsson BO (1994) Expression of an endogenous retrovirus (ERV3 HERV-R) in human reproductive and embryonic tissues--evidence for a function for envelope gene products. *Ups J Med Sci* 99: 113-120.
 26. Andersson AC, Venables PJ, Tönjes RR, Scherer J, Eriksson L, et al. (2002) Developmental expression of HERV-R (ERV3) and HERV-K in human tissue. *Virology* 297: 220-225.
 27. Prudhomme S, Bonnaud B, Mallet F (2005) Endogenous retroviruses and animal reproduction. *Cytogenet Genome Res* 110: 353-364.
 28. Kim HS, Yi JM, Hirai H, Huh JW, Jeong MS, et al. (2006) Human Endogenous Retrovirus (HERV)-R family in primates: Chromosomal location, gene expression, and evolution. *Gene* 370: 34-42.
 29. Boyd MT, Bax CM, Bax BE, Bloxam DL, Weiss RA (1993) The human endogenous retrovirus ERV-3 is upregulated in differentiating placental trophoblast cells. *Virology* 196: 905-909.
 30. Katsumata K, Ikeda H, Sato M, Ishizu A, Kawarada Y, et al. (1999) Cytokine regulation of env gene expression of human endogenous retrovirus-R in human vascular endothelial cells. *Clin Immunol* 93: 75-80.
 31. Takeuchi K, Katsumata K, Ikeda H, Minami M, Wakisaka A, et al. (1995) Expression of endogenous retroviruses, ERV3 and lambda 4-, in synovial tissues from patients with rheumatoid arthritis. *Clin Exp Immunol* 99: 338-344.
 32. Lee JR, Ahn K, Kim YJ, Jung YD, Kim HS (2012) Radiation-induced human endogenous retrovirus (HERV)-R env gene expression by epigenetic control. *Radiat Res* 178: 379-384.
 33. Ahn K, Kim HS (2009) Structural and quantitative expression analyses of HERV gene family in human tissues. *Mol Cells* 28: 99-103.
 34. Das AK, Sato M, Story MD, Peyton M, Graves R, et al. (2006) Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. *Cancer Res* 66: 9601-9608.
 35. Jung IL, Kang HJ, Kim KC, Kim IG (2010) PTEN/pAkt/p53 signaling pathway correlates with the radioresponse of non-small cell lung cancer. *Int J Mol Med* 25: 517-523.
 36. Lin TY, Chang JT, Wang HM, Chan SH, Chiu CC, et al. (2010) Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. *Int J Radiat Oncol Biol Phys* 78: 246-256.
 37. Schiegnitz E, Kämmerer PW, Rode K, Schorn T, et al. (2016) Growth differentiation factor 15 as a radiation-induced marker in oral carcinoma increasing radiation resistance. *J Oral Pathol Med* 45: 63-69.
 38. Heavey S, O'Byrne KJ, Gately K (2014) Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. *Cancer Treat Rev* 40: 445-456.
 39. Baumann M, Krause M, Dikomey E, Dittmann K, Dörr W, et al. (2007) EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. *Radiother Oncol* 83: 238-248.
 40. Krause M, Zips D, Thames HD, Kummermehr J, Baumann M (2006) Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. *Radiother Oncol* 80: 112-122.
 41. Downey RF, Sullivan FJ, Wang-Johanning F, Ambs S, et al. (2015) Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice? *Int J Cancer* 137: 1249-1257.
 42. Liu SL, Miller AD (2007) Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein. *Oncogene* 26: 789-801.
 43. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. *Nature* 408: 307-310.
 44. Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. *Nat Rev Drug Discov* 7: 979-987.
 45. Zwang Y, Oren M, Yarden Y (2012) Consistency test of the cell cycle: roles for p53 and EGR1. *Cancer Res* 72: 1051-1054.
 46. Huang CL, Yokomise H, Miyatake A (2007) Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers. *Future Oncol* 3: 83-93.
 47. Green DR, Llambi F (2015) Cell Death Signaling. *Cold Spring Harb Perspect Biol* 7.